The biologics mepolizumab, dupilumab and benralizumab showed minimal differences in efficacy and safety in treating eosinophilic asthma, according to a review of eight studies published in The Journal of Allergy and Clinical Immunology.
However, these studies offered low to moderate certainty of evidence, Ayobami T. Akenroye, MBChB, MPH, an associate physician with the division of allergy and clinical immunology at Brigham and Women’s Hospital in Boston, and colleagues found.
“The number of monoclonal antibodies approved for the treatment of asthma continues to rise, and a